▼ bearish
Impact
PhasePhase 2
Time to marketNot stated
laromestrocel Updated Oct 26
What to watch
The next near-term event is the AHA 2026 Scientific Sessions podium presentation of the ELPIS II secondary endpoint data (date TBD). A positive reception could provide a short-term bounce, but the primary endpoint failure already limits the HLHS regulatory path. The bigger binary is the outcome of the strategic alternatives review, a sale or partnership could unlock value, while failure to find a deal could force a dilutive financing or a wind-down. Watch for 8-K filings for any 8-K regarding a potential sale, financing or Nasdaq compliance notice.
Bull case
- Updated ELPIS II secondary endpoint analysis (Oct 26, 2026) showed a pre-specified secondary endpoint, Major Adverse Cardiac Events (MACE), achieved statistical significance with 8 events in the standard-of-care arm vs 1 in the laromestrocel arm (p=0.043), and the data was selected for a Late-Breaking Science podium presentation at AHA 2026 Scientific Sessions.
- Phase 2b frailty results published in Cell Stem Cell (Feb 2026) showed laromestrocel improved physical condition in aging-related frailty patients at 9 months, and the company was selected as an XPRIZE Healthspan finalist.
- Phase 2a CLEAR MIND Alzheimer's results published in Nature Medicine (March 2025) showed laromestrocel may reduce cognitive decline and brain atrophy; additional neuroinflammation data presented at AAIC 2026.
Bear case
- ELPIS II Phase 2b (HLHS) missed its primary endpoint (RVEF at 12 months, p=0.8336), severely damaging the lead indication's regulatory path forward and triggered a strategic review of all options including a potential sale.
- Cash runway extends only into Q4 2026 per the March private placement terms; with no revenue and a $4.7M quarterly net loss, the company likely needs additional capital soon, risking severe dilution.
- Chief Medical Officer Dr. Nataliya Agafonova resigned effective Oct 14, 2026 with no replacement named, creating operational uncertainty in clinical execution.